KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Total Debt (2016 - 2026)

Gsk has reported Total Debt over the past 18 years, most recently at -$26.0 billion for Q1 2026.

  • For Q1 2026, Total Debt rose 7.52% year-over-year to -$26.0 billion; the TTM value through Mar 2026 reached -$26.0 billion, up 7.52%, while the annual FY2025 figure was -$26.7 billion, 222.86% down from the prior year.
  • Total Debt for Q1 2026 was -$26.0 billion at Gsk, up from -$26.7 billion in the prior quarter.
  • Over five years, Total Debt peaked at $22.3 billion in Q4 2023 and troughed at -$30.5 billion in Q2 2022.
  • A 5-year average of -$18.1 billion and a median of -$26.7 billion in 2025 define the central range for Total Debt.
  • Biggest five-year swings in Total Debt: soared 49.59% in 2022 and later plummeted 222.86% in 2025.
  • Year by year, Total Debt stood at $21.5 billion in 2022, then grew by 3.97% to $22.3 billion in 2023, then fell by 2.65% to $21.8 billion in 2024, then plummeted by 222.86% to -$26.7 billion in 2025, then increased by 2.7% to -$26.0 billion in 2026.
  • Business Quant data shows Total Debt for GSK at -$26.0 billion in Q1 2026, -$26.7 billion in Q4 2025, and -$27.6 billion in Q3 2025.